Coya Therapeutics (NASDAQ: COYA) congratulated its long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the 2025 Nobel Prize in Physiology or Medicine for his discovery of regulatory T cells (Tregs) and their essential role in maintaining immune balance. Dr. Sakaguchi's pioneering research transformed modern immunology, revealing how these specialized cells protect the body from excessive inflammation and autoimmune disease -- and opening new therapeutic frontiers that Coya is now advancing in the clinic.

Dr. Sakaguchi has provided scientific guidance to Coya in translating Treg biology into therapeutic innovation for diseases of immune dysfunction. His discovery that a distinct class of immune cells suppresses overactive immune responses has informed the company's approach to restoring immune homeostasis in chronic neurodegenerative and inflammatory conditions.

"Dr. Sakaguchi's Nobel Prize is a recognition of one of the most important immunological discoveries of our time," said Dr. Howard Berman, Executive Chairman of Coya Therapeutics. "We congratulate Dr. Sakaguchi and are honored to have benefited from his wisdom and guidance; we are committed to carrying forward his vision to harness the power of regulatory T cells to potentially improve the lives of patients suffering from diseases of immune dysfunction."

Translating Nobel-Winning Science into Clinical Impact

Coya's therapeutic platform builds directly upon Dr. Sakaguchi's foundational work, applying Treg modulation to restore immune balance and reduce neuroinflammation in diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease.

The company recently initiated its Phase 2 ALSTARS trial evaluating COYA 302, a dual-mechanism biologic designed to enhance Treg activity and suppress inflammation in ALS. This milestone follows FDA clearance of its Investigational New Drug (IND) application and reflects growing recognition of Treg biology as a transformative therapeutic pathway. The program is supported by a strategic partnership with Dr. Reddy's Laboratories (NYSE: RDY), which provides non-dilutive milestone payments, manufacturing expertise, and commercialization support.

Beyond ALS, Coya has completed enrollment in an Investigator Initiated proof-of-concept study in frontotemporal dementia at Houston Methodist led by Dr. Stanley Appel and Dr. Ali Faridar, with topline results expected in the fourth quarter of 2025. Additionally, preclinical studies of COYA 303 -- a combination of low-dose IL-2 and a GLP-1 receptor agonist -- have demonstrated potent anti-inflammatory and neuroprotective effects in models of Alzheimer's disease, reinforcing the broad potential of Coya's platform.

The post Coya Therapeutics Scientific Advisor Awarded Nobel Prize for Discovery of Regulatory T Cells, Foundational to Company's Therapeutic Platform appeared first on PRISM MarketView.

COMTEX_469348093/2927/2025-10-07T15:01:17